News

Liver Disease

Novo Nordisk To Acquire Dicerna Pharmaceuticals for $3.3 Billion

Kimberly Redmond | Equities.com |

Danish drugmaker Novo Nordisk A/S plans to buy US-based biotech Dicerna Pharmaceuticals Inc in a $3.3 billion cash deal.

Under the terms of the agreement announced Thursday, Novo will pay $38.25 per share in cash, an 80% premium to Dicerna’s closing price on Nov. 17. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435 

Based in Lexington, Massachusetts, Dicerna’s drug development has...


Sponsored Financial Content

Market Movers